{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:47:23Z","timestamp":1782222443499,"version":"3.54.5"},"reference-count":128,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Edward P. Evans Foundation","award":["NIH\/NIDDK R01DK102792"],"award-info":[{"award-number":["NIH\/NIDDK R01DK102792"]}]},{"name":"Edward P. Evans Foundation","award":["NIH\/NCI R01CA222518"],"award-info":[{"award-number":["NIH\/NCI R01CA222518"]}]},{"name":"Edward P. Evans Foundation","award":["R01CA266604"],"award-info":[{"award-number":["R01CA266604"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The currently available therapeutic options for patients with TP53-mutated acute myeloid leukemia (AML) are insufficient, as they translate to a median overall of only 6\u20139 months, and less than 10% of patients undergoing the most aggressive treatments, such as intensive induction therapy and allogeneic hematopoietic stem cell transplantation, will be cured. The lack of clear differences in outcomes with different treatments precludes the designation of a standard of care. Recently, there has been growing attention on this critical area of need by way of better understanding the biology of TP53 alterations and the disparities in outcomes among patients in this molecular subgroup, reflected in the development and testing of agents with novel mechanisms of action. Promising preclinical and efficacy data exist for therapies that are directed at the p53 protein rendered dysfunctional via mutation or that inhibit the CD47\/SIRP\u03b1 axis or other immune checkpoints such as TIM-3. In this review, we discuss recently attractive and emerging therapeutic agents, their preclinical rationale and the available clinical data as a monotherapy or in combination with the currently accepted backbones in frontline and relapsed\/refractory settings for patients with TP53-mutated AML.<\/jats:p>","DOI":"10.3390\/cancers14102434","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T09:27:56Z","timestamp":1652520476000},"page":"2434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian F.","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","article-title":"More than 1 tp53 abnormality is a dominant characteristic of pure erythroid leukemia","volume":"129","author":"Benton","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Badar, T., Atallah, E., Shallis, R.M., Goldberg, A.D., Patel, A., Abaza, Y., Bewersdorf, J.P., Saliba, A.N., Correia, G.S.C., and Murthy, G. (2022). Outcomes of tp53-mutated aml with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am. J. Hematol.","DOI":"10.1002\/ajh.26546"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","article-title":"Tp53 mutations predict poorer responses to cpx-351 in acute myeloid leukemia","volume":"132","author":"Goldberg","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"Tp53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"Tp53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with tp53-mutated acute myeloid leukemia or myelodysplastic syndromes: A single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in tp53-mutated myelodysplastic syndromes and acute myeloid leukemia: A phase ii study by the groupe francophone des myelodysplasies (gfm)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (apr-246) and azacitidine in tp53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of tp53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrc1455","article-title":"Post-translational modification of p53 in tumorigenesis","volume":"4","author":"Bode","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (aml) on outcome in 2853 adult patients with newly diagnosed aml","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"Tp53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"Tp53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal tp53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of tp53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"key":"ref_27","first-page":"1001","article-title":"The mdm2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/leu.2016.350","article-title":"P53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of tp53 mutational status","volume":"31","author":"Hu","year":"2017","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of tp53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant tp53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"Tp53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related mds\/aml","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/bcj.2015.59","article-title":"Tp53 mutations in de novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 study of cpx-351 versus 7+3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (aml)","volume":"134","author":"Lindsley","year":"2019","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-142595","article-title":"Real world outcomes of liposomal daunorubicin and cytarabine versus 7+3 in patients with secondary acute myeloid leukemia","volume":"136","author":"Madarang","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: A randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase iii trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","article-title":"Outcomes with lower intensity therapy in tp53-mutated acute myeloid leukemia","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase ii study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and mir-29b predictive significance in older aml patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"Tp53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in tp53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: A single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with cpx-351 and impact on the outcome of high-risk aml patients: A multicentric french cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","article-title":"Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for aml patients in the united states","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the lrf aml14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (aml) in older patients: The results of the united kingdom medical research council aml11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the german acute myeloid leukemia cooperative group","volume":"27","author":"Buchner","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.blre.2019.100639","article-title":"The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia","volume":"40","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.clml.2011.02.003","article-title":"Older patients with acute myeloid leukemia benefit from intensive chemotherapy: An update from the swedish acute leukemia registry","volume":"11","author":"Juliusson","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: A population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with aml receiving hypomethylating agents: A large population-based study in the united states","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_63","unstructured":"Zeidan, A.M., Fenaux, P., Gobbi, M., Mayer, J., Roboz, G.J., Krauter, J., Robak, T., Kantarjian, H.M., Novak, J., and Jedrzejczaket, W.W. (2020, January 12). Comparative results of azacitidine and decitabine from a large prospective phase 3 study in treatment naive acute myeloid leukemia (tn-aml) not eligible for intensive therapy. Proceedings of the European Hematology Association 2020 Meeting, Hamburg, Germany. Abstract s142."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2018-99-115367","article-title":"Five-day versus ten-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase ii study","volume":"132","author":"Short","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Pollyea, D.A., Pratz, K.W., Wei, A.H., Pullarkat, V.A., Jonas, B.A., Recher, C., Babu, S., Schuh, A.C., Dail, M., and Sun, Y. (2021, January 11). Outcomes in patients with poor-risk cytogenetics with or without tp53 mutations treated with venetoclax combined with hypomethylating agents. Proceedings of the American Society of Hematology 2021 Meeting, Atlanta, GA, USA. Abstract 224.","DOI":"10.1182\/blood-2021-145639"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Grenet, J., Jain, A.G., Burkart, M., Waksal, J., Famulare, C., Numan, Y., Stahl, M., Mckinnell, Z., Ball, B., and Ma, X. (2021, January 10\u201314). Comparing outcomes between liposomal daunorubicin\/cytarabine (cpx-351) and hma+venetoclax as frontline therapy in acute myeloid leukemia. Proceedings of the American Society of Hematology 2021 Meeting, Atlanta, GA, USA. Abstract 32.","DOI":"10.1182\/blood-2021-145947"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2010.01557.x","article-title":"Apr-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells","volume":"86","author":"Ali","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of prima-1(met) (apr-246) and 5-azacitidine in tp53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"key":"ref_69","unstructured":"(2020, December 28). Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in Tp53 Mutant myelodysPlastic Syndromes (Mds). Aprea Therapeutics. Available online: https:\/\/ir.Aprea.Com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Sallman, D.A., Komrokji, R.S., Dezern, A.E., Sebert, M., Garcia-Manero, G., Rahm\u00e9, R., Steensma, D.P., Rahm\u00e9, R., Lehmann, J., and Roboz, G.J. (2021, January 11). Long term follow-up and combined phase 2 results of eprenetapopt (apr-246) and azacitidine (aza) in patients with tp53 mutant myelodysplastic syndromes (mds) and oligoblastic acute myeloid leukemia (aml). Proceedings of the American Society of Hematology 2021 Meeting, Atlanta, GA, USA. Abstract 246.","DOI":"10.1182\/blood-2021-153286"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase ii trial of eprenetapopt (apr-246) in combination with azacitidine (aza) as maintenance therapy for tp53 mutated aml or mds following allogeneic stem cell transplantation (sct)","volume":"138","author":"Mishra","year":"2021","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2021-148940","article-title":"Phase i and expansion study of eprenetapopt (apr-246) in combination with venetoclax (ven) and azacitidine (aza) in tp53-mutant acute myeloid leukemia (aml)","volume":"138","author":"Goldberg","year":"2021","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system xc(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1535-7163.MCT-21-0067","article-title":"Slc7a11 is a superior determinant of apr-246 (eprenetapopt) response than tp53 mutation status","volume":"20","author":"Fujihara","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"Apr-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2022","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in aml","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-cd47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1084\/jem.20120502","article-title":"Disruption of sirpalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts","volume":"209","author":"Theocharides","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The cd47-sirpalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The cd47-signal regulatory protein alpha (sirpa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1121629109","article-title":"Antibody therapy targeting the cd47 protein is effective in a model of aggressive metastatic leiomyosarcoma","volume":"109","author":"Edris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"Cd47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"Cd47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-cd47 antibodies stimulate phagocytosis and promote elimination of aml cells","volume":"236","author":"Wang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_85","first-page":"15","article-title":"Alx148 enhances the depth and durability of response to multiple aml therapies","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0000000000000691","article-title":"Targeting the cluster of differentiation 47\/signal-regulatory protein alpha axis in myeloid malignancies","volume":"29","author":"Wang","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-cd47 antibody magrolimab (5f9) in combination with azacitidine is effective in mds and aml patients: Ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Daver, N., Konopleva, M., Maiti, A., Kadia, T.M., Dinardo, C.D., Loghavi, S., Pemmaraju, N., Jabbour, E.J., Montalban-Bravo, G., and Tang, G. (2021, January 12). Phase i\/ii study of azacitidine (aza) with venetoclax (ven) and magrolimab (magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (aml) and relapsed\/refractory (r\/r) aml. Proceedings of the American Society of Hematology 2021 Meeting, Atlanta, GA, USA. Abstract 371.","DOI":"10.1182\/blood-2021-153638"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","article-title":"Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.2011.41.5505","article-title":"Deregulated expression of evi1 defines a poor prognostic subset of mll-rearranged acute myeloid leukemias: A study of the german-austrian acute myeloid leukemia study group and the dutch-belgian-swiss hovon\/sakk cooperative group","volume":"31","author":"Groschel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (mbg453) in combination with hypomethylating agents (hmas) in patients (pts) with very high\/high-risk myelodysplastic syndrome (vhr\/hr-mds) and acute myeloid leukemia (aml): Final analysis from a phase ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"Tp53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in aml","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.leukres.2020.106489","article-title":"Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1\/1b study small star, filled","volume":"100","author":"Yee","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the mdm2 inhibitor amg 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Adv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class nedd8-activating enzyme inhibitor, combined with azacitidine in patients with aml","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e000413","DOI":"10.1136\/jitc-2019-000413","article-title":"The fully human anti-cd47 antibody srf231 exerts dual-mechanism antitumor activity via engagement of the activating receptor cd32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Garcia-Manero, G., Erba, H.P., Sanikommu, S.R., Altman, J.K., Sayar, H., Scott, B.L., and Fond, A.P. (2021, January 12). Evorpacept (alx148), a cd47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: A phase 1\/2 study in patients with myelodysplastic syndrome (aspen-02). Proceedings of the American Society of Hematology Meeting, Atlanta, GA, USA. Abstract 2601.","DOI":"10.1182\/blood-2021-146547"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"Tti-621 (sirpalphafc): A cd47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ndt\/gfr547","article-title":"Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function","volume":"27","author":"McCullough","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase iii study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase i study of the cd47 blocker tti-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_102","unstructured":"Trillium Therapeutics, Inc. (2021, June 10). Trillium Therapeutics Provides Data Update, Announces Phase 1b\/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes. Available online: https:\/\/s22.Q4cdn.Com\/183592819\/files\/doc_news\/2021\/04\/2021-04-28-rd-day-press-release-final."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-134391","article-title":"A phase i\/iia study of lemzoparlimab, a monoclonal antibody targeting cd47, in patients with relapsed and\/or refractory acute myeloid leukemia (aml) and myelodysplastic syndrome (mds): Initial phase i results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Macip","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri.2016.99","article-title":"Emerging roles of p53 and other tumour-suppressor genes in immune regulation","volume":"16","author":"Mandinova","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1158\/0008-5472.CAN-11-4134","article-title":"The human tlr innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells","volume":"72","author":"Shatz","year":"2012","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601911409747","article-title":"Inflammation and p53: A tale of two stresses","volume":"2","author":"Gudkov","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1096\/fj.04-3213fje","article-title":"P53 is a suppressor of inflammatory response in mice","volume":"19","author":"Komarova","year":"2005","journal-title":"FASEB J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"Pd-l1 (b7-h1) and pd-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ncb2556","article-title":"Synthetic lethality between rb, p53 and dicer or mir-17-92 in retinal progenitors suppresses retinoblastoma formation","volume":"14","author":"Nittner","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1073\/pnas.0808042106","article-title":"P53 represses c-myc through induction of the tumor suppressor mir-145","volume":"106","author":"Sachdeva","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature08199","article-title":"Modulation of microrna processing by p53","volume":"460","author":"Suzuki","year":"2009","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","article-title":"Pdl1 regulation by p53 via mir-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"Tp53 mutations in myelodysplastic syndromes and secondary aml confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting tim-3 and pd-1 pathways to reverse t cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"88904","DOI":"10.18632\/oncotarget.21492","article-title":"Functional expression of tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes","volume":"8","author":"Asayama","year":"2017","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A tim-3\/gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_125","unstructured":"Konopleva, M.Y., Rollig, C., Cavenagh, J., Deeren, D., Girshova, L., Krauter, J., Martinelli, G., and Montesinos, P. (2020, January 12). A randomized double-blind phase 3 trial of cytarabine with mdm2 inhibitor idasanutlin or placebo in relapsed\/refractory acute myeloid leukemia (r\/r aml): Primary analysis results of the mirros study. Proceedings of the 25th Congress of the European Hematology Association 2020, Frankfurt, Germany. Abstract ep532."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with aml","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","article-title":"Pevonedistat and azacitidine upregulate noxa (pmaip1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia","volume":"107","author":"Cojocari","year":"2021","journal-title":"Haematologica"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2021-153682","article-title":"Azacitidine, venetoclax and pevonedistat as frontline therapy for patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy: Results from a phase i\/ii study","volume":"138","author":"Short","year":"2021","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:49Z","timestamp":1760137849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":128,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14102434"],"URL":"https:\/\/doi.org\/10.3390\/cancers14102434","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]}}}